Clarient receives patent for Mammostrat breast cancer prognostic test

Clarient receives patent for Mammostrat breast cancer prognostic test
Clarient, Inc. a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that the United States Patent and Trademark Office and the European Patent Office have allowed patents covering the technology behind Clarient Insight Dx Mammostrat, a test designed to aid in the classification of the risk of recurrence of breast cancer …

Read more on News-Medical-Net